Pricing of Outlook Therapeutics' ONS-5010 a crucial factor in the wider market

28 April 2022

Outlook Therapeutics (Nasdaq: OTLK) recently submitted a Biologics License Application to the US Food and Drug Administration for ONS-5010 (bevacizumab-vikg) for the treatment of wet age-related macular degeneration (wAMD).

If ONS-5010 is approved, the pricing of the therapy would be significant for its introduction into the wider market, says data and analytics company GlobalData. The proposed brand name for the drug is Lytenava

AMD is associated with breakdown of the macular region of the retina that can cause significant vision loss. Among the different forms of AMD, only wAMD has approved treatment options. The standard of care for wAMD patients is anti-VEGF therapy, which can slow or inhibit the growth and leakage of blood vessels in the retina.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK